This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans
by Zacks Equity Research
MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
by Zacks Equity Research
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
ANIPNegative Net Change ACADPositive Net Change SNDXNegative Net Change ARQTPositive Net Change
biotechs earnings
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
by Zacks Equity Research
Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
ALKSNegative Net Change JAZZNegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs earnings medical
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
FOLDPositive Net Change CPRXPositive Net Change ANIPNegative Net Change ACADPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
by Zacks Equity Research
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
ALKSNegative Net Change FOLDPositive Net Change CRMDPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
FOLDPositive Net Change ANIPNegative Net Change ACADPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
by Zacks Equity Research
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ALKSNegative Net Change FOLDPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
by Zacks Equity Research
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
AZNPositive Net Change NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs pharmaceuticals
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?
by Zacks Equity Research
VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.
VRTXPositive Net Change ANIPNegative Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
by Zacks Equity Research
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
ANIPNegative Net Change NTLAPositive Net Change MIRMPositive Net Change ARQTPositive Net Change
biotechs earnings
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
by Zacks Equity Research
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
RHHBYNegative Net Change ALKSNegative Net Change EXELNegative Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
by Zacks Equity Research
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
REGNNegative Net Change BEAMPositive Net Change FOLDPositive Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
BEAMPositive Net Change FOLDPositive Net Change ANIPNegative Net Change MDGLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
by Zacks Equity Research
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
NVONegative Net Change LLYPositive Net Change BEAMPositive Net Change FOLDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
by Zacks Equity Research
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
ALKSNegative Net Change FOLDPositive Net Change CRMDPositive Net Change EXASNegative Net Change
biotechs earnings
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
by Zacks Equity Research
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
RHHBYNegative Net Change SRPTPositive Net Change ARWRPositive Net Change
biotechs earnings gene-editing gene-therapy medical pharmaceuticals
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
by Zacks Equity Research
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
BEAMPositive Net Change FOLDPositive Net Change ZTSNegative Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint
by Zacks Equity Research
VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.
VRTXPositive Net Change ANIPNegative Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs pharmaceuticals
Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View
by Zacks Equity Research
HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.
RHHBYNegative Net Change JNJPositive Net Change HALONegative Net Change ARGXPositive Net Change
biotechs earnings
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
by Zacks Equity Research
Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.
JAZZNegative Net Change ANIPNegative Net Change AXSMPositive Net Change NTLAPositive Net Change
biotechs earnings
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
by Zacks Equity Research
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
TGTXPositive Net Change ANIPNegative Net Change NTLAPositive Net Change ARQTPositive Net Change
biotechs earnings
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
BEAMPositive Net Change NBIXPositive Net Change FOLDPositive Net Change XENEPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
by Zacks Equity Research
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
GSKNegative Net Change PFENegative Net Change MRKNegative Net Change MRNANegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals